Dashboard
Manage Tickers

AMED


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

contessa-health-a-subsidiary-of-amedisys-announced-they-have-been-selected-by-the-centers-for-medicare--medicaid-services-to-participate-in-a-new-medicare-alternative-payment-model-designed-to-support-people-living-with-dementia-and-their-caregivers
Contessa Health, A Subsidiary Of Amedisys ...
08/21/2024 10:31:28

deutsche-bank-downgrades-amedisys-to-hold-maintains-price-target-to-101
Deutsche Bank Downgrades Amedisys to Hold,...
07/31/2024 11:48:30

Deutsche Bank analyst Justin Bowers downgrades Amedisys (NASDAQ:AMED) from Buy to Hold and maintains the price target from $...

cantor-fitzgerald-reiterates-neutral-on-amedisys-maintains-101-price-target
Cantor Fitzgerald Reiterates Neutral on Am...
07/25/2024 13:52:56

Cantor Fitzgerald analyst Sarah James reiterates Amedisys (NASDAQ:AMED) with a Neutral and maintains $101 price target.

amedisys-q2-eps-132-beats-118-estimate-sales-59119m-beat-57882m-estimate
Amedisys Q2 EPS $1.32 Beats $1.18 Estimate...
07/24/2024 20:57:09

Amedisys (NASDAQ:AMED) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.18 by 11....

william-blair-downgrades-amedisys-to-market-perform
William Blair Downgrades Amedisys to Marke...
07/01/2024 12:38:39

William Blair analyst Matt Larew downgrades Amedisys (NASDAQ:AMED) from Outperform to Market Perform.

cantor-fitzgerald-reiterates-neutral-on-amedisys-maintains-101-price-target
Cantor Fitzgerald Reiterates Neutral on Am...
04/25/2024 14:17:34

Cantor Fitzgerald analyst Sarah James reiterates Amedisys (NASDAQ:AMED) with a Neutral and maintains $101 price target.

amedisys-q1-2024-adj-eps-103-beats-102-estimate-sales-571400m-beat-565380m-estimate
Amedisys Q1 2024 Adj EPS $1.03 Beats $1.02...
04/24/2024 20:47:39

Amedisys (NASDAQ:AMED) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $1.02 by 0.9...

raymond-james-maintains-market-perform-on-amedisysto-market-perform
Raymond James Maintains Market Perform on ...
03/26/2024 17:21:43

Raymond James analyst John Ransom maintains Amedisys (NASDAQ:AMED) from Market Perform to Market Perform.

rbc-capital-maintains-outperform-on-amedisys-raises-price-target-to-100
RBC Capital Maintains Outperform on Amedis...
03/25/2024 12:06:36

RBC Capital analyst Ben Hendrix maintains Amedisys (NASDAQ:AMED) with a Outperform and raises the price target from $97 to $...

amedisys-q4-2023-adj-eps-0940-misses-1030-estimate-sales-570800m-beat-567713m-estimate
Amedisys Q4 2023 Adj EPS $0.940 Misses $1....
03/05/2024 21:19:11

Amedisys (NASDAQ:AMED) reported quarterly earnings of $0.940 per share which missed the analyst consensus estimate of $1.030 by...

amedisys-q4-2023-adj-eps-094-misses-103-estimate-sales-57080m-beat-56771m-estimate
Amedisys Q4 2023 Adj EPS $0.94 Misses $1.0...
02/21/2024 22:09:50

Amedisys (NASDAQ:AMED) reported quarterly earnings of $0.94 per share which missed the analyst consensus estimate of $1.03 by 8...

amedisys-offers-molecular-testing-for-rapid-and-accurate-infection-diagnosis-in-collaboration-with-patient-choice-laboratories
Amedisys Offers Molecular Testing For Rapi...
02/08/2024 12:35:13

Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering adva...

amedisys-q3-adj-eps-098-misses-108-estimate-sales-55620m-miss-56127m-estimate
Amedisys Q3 Adj. EPS $0.98 Misses $1.08 Es...
10/24/2023 20:44:39

Amedisys (NASDAQ:AMED) reported quarterly earnings of $0.98 per share which missed the analyst consensus estimate of $1.08 by 9...

cantor-fitzgerald-maintains-neutral-rating-for-amedisys-heres-what-you-need-to-know
Cantor Fitzgerald Maintains Neutral Rating...
09/14/2023 17:00:18

cantor-fitzgerald-maintains-neutral-on-amedisys-raises-price-target-to-101
Cantor Fitzgerald Maintains Neutral on Ame...
09/14/2023 13:11:31

Cantor Fitzgerald analyst Sarah James maintains Amedisys (NASDAQ:AMED) with a Neutral and raises the price target from $100 ...

td-cowen-maintains-market-perform-on-amedisys-raises-price-target-to-101
TD Cowen Maintains Market Perform on Amedi...
07/31/2023 19:43:15

TD Cowen analyst Gary Taylor maintains Amedisys (NASDAQ:AMED) with a Market Perform and raises the price target from $84 to ...

what-11-analyst-ratings-have-to-say-about-amedisys
What 11 Analyst Ratings Have To Say About ...
07/27/2023 14:00:20

credit-suisse-reiterates-neutral-on-amedisys-maintains-101-price-target
Credit Suisse Reiterates Neutral on Amedis...
07/27/2023 12:46:57

Credit Suisse analyst Jonathan Yong reiterates Amedisys (NASDAQ:AMED) with a Neutral and maintains $101 price target.

amedisys-q2-adj-eps-137-beats-109-estimate-sales-55300m-miss-56820m-estimate
Amedisys Q2 Adj EPS $1.37 Beats $1.09 Esti...
07/26/2023 20:36:34

Amedisys (NASDAQ:AMED) reported quarterly adj earnings of $1.37 per share which beat the analyst consensus estimate of $1.09 by...

benzingas-top-ratings-upgrades-downgrades-for-july-6-2023
Benzinga's Top Ratings Upgrades, Downgrade...
07/06/2023 15:02:19

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION